Results of the ALLHAT trial: Is the debate about initial antihypertensive drug therapy over?

Journal of Clinical Hypertension

Volumn 5, Issue 1, 2003, Pages 5-8

  Moser, Marvin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLESTEROL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDRALAZINE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; RENIN; RESERPINE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; URIC ACID;

BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; METABOLIC DISORDER; MONOTHERAPY; MORTALITY; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0037274706     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.02259.x     Document Type: Editorial

References (36)

1. Antihypertensive Therapy and Lipid Lowering Heart Attack Trial (ALLHAT) Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2000;283:1967-1975.
2. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
3. Ames RP. The influence of non β-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension? Am Heart J. 1987;114:998-1006.
4. Zussman RM. Alternatives to traditional antihypertensive therapy [editorial]. Hypertens. 1986;8:837-842.
5. Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J. 1989;117:911-949.
6. Hebert P, Moser M, Mayer J, et al. Recent evidence of drug therapy on mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
7. McInnes GT, Yeo WW, Ramsey LE, et al. Cardiotoxicity and diuretics: much speculation, little substance. J Hypertens. 1992;10:317-335.
8. Moser M. Suppositions and speculations-their possible effects on treatment decisions in the management of hypertension. Am Heart J. 1989;118:1362-1369.
9. Freis ED. Critique of the clinical importance of diuretic induced hypokalemia and elevated cholesterol levels. Arch Intern Med. 1989;149:2649-2658.
10. Moser M. Current hypertension management: separating fact from fiction. Cleve Clinic J Med. 1993;60:27-37.
11. Thompson WG. An assault on old friends: thiazide diuretics under siege. Am J Med Sci. 1990;300:152-158.
12. Papademetriou V, Fletcher R, Khatri IM, et al. Thiazide therapy is not a cause of arrhythmia in patient with systemic hypertension. Arch Intern Med. 1988;148:1272-1276
13. Holland OB, Nixon JV, Kuhnert I. Diuretic-induced ventricular ectopic activity. Am J Med. 1981;770:762-768.
14. Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med. 1984;80(4A):28-32.
15. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in the hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-1218.
16. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA. 1990;263:1795-1801.
17. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1993;153:154-183.
18. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
19. Moser M, Blaufox MD, Freis E, et al. Who really determines your patients' prescriptions? JAMA. 1991;265:498-500.
20. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;179:1813-1816.
21. SHEP Cooperative Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
22. Moser M. Diuretics should continue to be recommended as initial therapy in the treatment of hypertension. In: Puschett JB, Greenberg A, eds. Diuretics IV: Chemistry, Pharmacology and Clinical Applications. New York, NY: Exerpta Medica; 1993:465-477.
23. Neaton JD, Grimm RH, Prineas RJ, et al. for the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension study: final results. JAMA. 1993;270: 713-724.
24. Moser M, Setaro J. Antihypertensive drug therapy and regression of left ventricular hypertrophy: review with a focus on diuretics. Eur Heart J. 1991;12:1034-1039.
25. Moser M, Ross H. The treatment of hypertension in diabetic patients. Diabetes Care. 1993;16:542-547.
26. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
27. Moser M. Can the cost of care be contained and quality of care maintained in the management of hypertension? Arch Intern Med. 1994;154:1665-1672.
28. Moser M. Hypertension can be treated effectively without increasing the cost of care. J Human Hypertens. 1996;10(suppl 2):S33-S38.
29. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345:861-869.
30. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
31. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO HOPE substudy. Lancet. 2000;255:253-259.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). N Engl J Med. 2001;345:851-860.
33. Agodoa L, Appel L, Bakris G, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis, African American Study of Kidney Disease (AASK). A randomized controlled trial. JAMA. 2001;285:2719-2728.
34. Parving HH, Lennert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan Microalbuminuria Type II Diabetes in Hypertensive Patients (IRMA II). N Engl J Med. 2001;345:870-878.
35. Moser M. Diuretics revisited-again. J Clin Hypertens. 2001;3:136-138.
36. Moser M. Myths, Misconceptions and Heroics-The Story of the Treatment of Hypertension from the 1930s. Darien, CT: LeJacq Communications, Inc.; 2002.